Related Experiment Video
Updated: Nov 22, 2025
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
IL-17A polymorphism (rs2275913) and levels are associated with preeclampsia pathogenesis in Chinese patients
Xiao Lang1,2, Wei Liu1,2, Yanyan Hou1,2
1The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, 910 Hengshan Road, Shanghai, 200030, China.
Insights
Genetic variants in IL-17A are linked to higher IL-17A levels and increased preeclampsia risk. This study highlights IL-17A
Area of Science:
- Immunology
- Genetics
- Obstetrics
Background:
- Preeclampsia (PE) is a pregnancy complication affecting mother and infant.
- The role of IL-17A and IL-23 in PE pathogenesis requires further elucidation.
- Investigating genetic variants in inflammatory genes offers insight into PE development.
Purpose of the Study:
- To investigate the association between common genetic variants in IL-17A and IL-23A genes and preeclampsia (PE).
- To determine the relationship between serum levels of IL-17A, IL-23, and specific genetic polymorphisms in PE patients.
Main Methods:
- Serum IL-17A and IL-23 levels were measured using ELISA in 115 PE patients, 102 pregnant women, and 147 healthy women.
- Genetic polymorphisms in IL-17A, IL-23A, and IL-12B were genotyped using PCR-RFLP or TaqMan probe-based methods.
- Statistical analysis compared cytokine levels and genotype frequencies between PE patients and control groups.
Main Results:
- PE patients exhibited significantly elevated serum IL-17A levels compared to both pregnant and healthy women (P < 0.0001).
- Serum IL-23 levels did not differ significantly across clinical groups.
- Specific IL-17A (rs2275913) and IL-23A (rs11171806) variants were more prevalent in PE patients, suggesting a role in PE predisposition.
- IL-17A (rs2275913) mutants were associated with higher serum IL-17A levels.
Conclusions:
- IL-17A (rs2275913) variants are associated with elevated serum IL-17A levels.
- These IL-17A variants appear to predispose individuals to the development of preeclampsia.
Background:
Preeclampsia (PE) is a pregnancy-related condition that affects both the infant and the mother. Although the role of various inflammatory molecules in PE has been demonstrated, the importance of pro-inflammatory molecules such as IL-17A, IL-23 is not well understood. In the present investigation, a potential association of common genetic variants in the IL-17A and IL-23A genes with PE was investigated.
Methods:
115 PE clinically diagnosed patients who registered to the International Peace Maternity and Child Health Hospital were enrolled in this research. One hundred two pregnant women and 147 healthy Chinese women were also included. ELISA was used to measure IL-17A and IL-23 serum levels in all enrolled subjects. Common genetic polymorphisms in IL-17A (rs 2,275,913, rs1974226, and rs1974226), IL-23A (rs11171806), and IL-12B (rs3212227) were genotyped using the PCR-RFLP or TaqMan probe-based method.
Results:
Elevated serum IL-17A levels were found in PE patients compared to pregnant (P < 0.0001) and healthy women (P < 0.0001). However, IL-23 levels were comparable across various clinical groups. In addition, heterozygous (GA) and minor allele (A) for IL-17A (rs2275913) and IL-23A (rs11171806) were more prevalent in PE patients compared to pregnant women indicating an important role in the predisposition to PE growth. Interestingly, IL-17A (r 2,275,913) mutants were associated with elevated IL-17A levels relative to wild type (GG).
Conclusions:
IL-17A (rs2275913) variants are associated with higher serum levels of cytokine, and predisposed PE development.
More Related Videos
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
